An eczema patient in a Mount Sinai clinical trial and a Mount Sinai physician-scientist who led the trial discuss Dupixent® (dupilumab), the first biologic medicine approved by the U.S. Food and Drug Administration for the treatment of adults with moderate to severe atopic dermatitis. The drug was fast-tracked because it is a “breakthrough therapy” for a large population of adult patients who have uncontrolled AD and need safer and more effective long-term treatments.
source
